echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > The FDA and EMA have accepted marketing applications for bimekizumab for the treatment of psoriasis.

    The FDA and EMA have accepted marketing applications for bimekizumab for the treatment of psoriasis.

    • Last Update: 2020-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted marketing applications for UMB Pharmaceuticals' psoriasis treatment drug bimekizumab.
    UCC is seeking approval in the United States and the European Union for the treatment of bimekizumab with moderate to severe plaque-like psoriasis.
    approvals are based on data from the UCC Psoriasis Global Phase III Clinical Development Program.
    Phase III studies reached the main endpoint: patients treated with bimekizumab had a higher rate of skin removal at the 16th week than those treated with placebo and AbbVie Humira.
    addition, two studies have shown that bimekizumab is superior to existing biological therapies, including Janssen's Stelara and AbbVie's Humira.
    In addition to being a treatment for psoriasis, UCB is currently studying bimekizumab as a potential treatment for psoriasis arthritis, hyperlinearthritis, non-radial axial spinal arthritis, and purulent sweat adenitis. "After a series of positive Phase III data, we are pleased to announce that the FDA and EMA have accepted our application to use bimekizumab as a potential new treatment for psoriasis," said Emmanuel Caeymaex, executive vice president of UMB at
    UCB.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.